Such combinations could mitigate the side effects associated with immunotherapy—namely, the heightened risk of infections due to immunosuppressive agents like tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β) inhibitors [130,131]. The gene discussed is TNF; the disease is infection.